Molaei S, Dadkhah M, Asghariazar V, et al. The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies. Int Immunopharma 2020;92:107051. DOI: 10.1016/j.intimp.2020.107051.
Hodgson SH, Mansatta K, Mallett G, et al. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis 2020;21(2):e26–e35. DOI: 10.1016/S1473-3099(20)30773-8.
Voysey M, Clemens SA, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet 2020;397(10269):99–111. DOI: 10.1016/S0140-6736(20)32661-1.
Bharat Biotech Recruits 23,000 Volunteers ForCovaxin's Phase 3 Clinical Trial”. NDTV.com. 28 December 2020. Retrieved 3 January 2021.
Lin DY, Zeng D, Mehrotra DV, et al. Evaluating the efficacy of COVID-19 vaccines. Clin Infect Dis 2020. ciaa1863. DOI: 10.1093/cid/ciaa1863.
Emadi A, Chua JV, Talwani R, et al. Safety and efficacy of imatinib for hospitalized adults with COVID-19: a structured summary of a study protocol for a randomised controlled trial. Trials 2020;21(1):897. DOI: 10.1186/s13063-020-04819-9.
Lipsitch M, Dean NE. Understanding COVID-19 vaccine efficacy. Science 2020;370(6518):763–765. DOI: 10.1126/science.abe5938.